Trial Profile
A First in Human, Randomized, Double-blind, Single Ascending Dose, Phase Ia Clinical Study to Assess the Safety, Tolerability and Pharmacokinetic Parameters of CN128 Tablets in Thalassemia Patients Aged 16 and Above
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs CN 128 (Primary)
- Indications Thalassaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Hangzhou Zede Pharmaceutical Technology
- 17 Dec 2019 Status changed from recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 13 Sep 2018 Planned number of patients changed to 47.